Skip to main content

MedImmune gets FDA fast track for RSV vaccine – Biz Journal

By April 2, 2015News
www.medimmune

www.medimmune

Gaithersburg-based MedImmune says it has received fast-track designation from the Food and Drug Administration for its MEDI8897, a drug being developed to prevent respiratory infections in infants and young children caused by respiratory syncytial virus. “We are working with a sense of urgency to develop a next-generation RSV [treatment] that we believe has the potential to benefit hundreds of thousands more infants, both in the U.S. and around the world,” said Steve Projan, senior vice president of research and development and infectious diseases and vaccines at MedImmune. “If successful, the fast-track designation will enable us to more quickly deliver a preventative solution.”

{iframe}http://www.bizjournals.com/washington/news/2015/04/09/medimmune-gets-fda-fast-track-for-rsv-vaccine.html{/iframe}

You have successfully subscribed to the newsletter

There was an error while trying to send your request. Please try again.

BioHealth Innovation will use the information you provide on this form to be in touch with you and to provide updates and marketing.